About MediciNova
MediciNova is a company based in San Diego (United States) founded in 2000 by Yuichi Iwaki. MediciNova has raised $83.94 million across 5 funding rounds from investors including Sumitomo Mitsui Banking Corporation, CDIB Capital Group and Dr.Ci:Labo. The company has 13 employees as of December 31, 2024. MediciNova has completed 2 acquisitions, including AviGen and Aviagen. MediciNova operates in a competitive market with competitors including TFF Pharmaceuticals, Theravance Biopharma, Elastrin, Chance Pharmaceuticals and ReAlta Life Sciences, among others.
- Headquarter San Diego, United States
- Employees 13 as on 31 Dec, 2024
- Founders Yuichi Iwaki
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Medicinova, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$11.05 M (USD)-28.91as on Dec 31, 2024
-
EBITDA
-$12.65 M (USD)-28.08as on Dec 31, 2024
-
Total Equity Funding
$83.94 M (USD)
in 5 rounds
-
Latest Funding Round
$20 M (USD), Post-IPO
Jan 11, 2021
-
Investors
Sumitomo Mitsui Banking Corporation
& 14 more
-
Employee Count
13
as on Dec 31, 2024
-
Investments & Acquisitions
AviGen
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MediciNova
MediciNova is a publicly listed company on the NASDAQ with ticker symbol MNOV in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of MediciNova
MediciNova has successfully raised a total of $83.94M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MediciNova
MediciNova has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Sumitomo Mitsui Banking Corporation, CDIB Capital Group and Dr.Ci:Labo.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Sector-agnostic investments are made in early-stage Asia Pacific startups.
|
Locked | Locked | Locked |
Investor details for MediciNova
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MediciNova
MediciNova has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include AviGen and Aviagen.
Investment portfolio details for MediciNova
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Gene therapy products are developed for inherited and acquired diseases.
|
Locked | Locked | 1992 | Locked | |
|
Poultry breeding stock is supplied globally by Aviagen.
|
Locked | Locked | 1923 | Locked |
Complete acquisition details for MediciNova
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - MediciNova
Detailed financials for MediciNova
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Medicinova Comparisons
Peer comparison for MediciNova
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MediciNova
MediciNova operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TFF Pharmaceuticals, Theravance Biopharma, Elastrin, Chance Pharmaceuticals and ReAlta Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of inhalation products for chronic respiratory diseases
|
|
| Locked | Locked | Locked |
Therapeutics for inflammatory and immunological diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutic targets related to arterial and lung diseases
|
|
| Locked | Locked | Locked |
Inhalation therapies for pulmonology disorders are developed.
|
|
| Locked | Locked | Locked |
Therapeutic drugs for acute inflammatory and rare diseases are developed.
|
Detailed competitors of MediciNova
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Medicinova
Complete news archive for MediciNova
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MediciNova
MediciNova was founded in 2000.
MediciNova is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Yuichi Iwaki is the current CEO of MediciNova. They have also founded this company.
MediciNova is a funded company, having raised a total of $83.94M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at MediciNova is 13.
MediciNov is a biopharmaceutical company that develops novel, small-molecule therapeutics for the treatment of diseases with unmet needs. It holds rights to a diversified portfolio of clinical and preclinical product candidates. Their pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, COPD exacerbations, multiple sclerosis, and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor, and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. Focusing on its two prioritized product candidates, MN-221, for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations, and ibudilast (MN-166AV411).
MediciNova's top competitors include TFF Pharmaceuticals, Theravance Biopharma and ReAlta Life Sciences.
Yes, MediciNova is publicly traded on NASDAQ under the ticker symbol MNOV.
MediciNova has 15 investors. Key investors include Sumitomo Mitsui Banking Corporation, CDIB Capital Group, Dr.Ci:Labo, 3D Investment Partners, and Aspire Capital.
The ticker symbol of MediciNova is MNOV on NASDAQ.